Business Standard

Strides Pharma dips 6% after it temporarily suspends Ranitidine sales in US

The stock of pharmaceuticals company was trading lower for the fifth straight day, slipping 14 per cent, as against a 2 per cent rise in the benchmark S&P BSE Sensex during the week.

drugs, medicines, USFDA
Premium

SI Reporter Mumbai
Strides Pharma Science hit a 52-week low of Rs 309 per share, down 6 per cent on the BSE, on Friday after the company announced suspension of sales of Ranitidine tablet in the US market. 

“While the company conducts the relevant tests mandated by the United States Food and Drug Administration (US FDA), it has suspended sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA,” Strides Pharma said in a regulatory filing today. READ FILING HERE

On Wednesday, the company informed

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 27 2019 | 11:24 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com